首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1424371

吸入劑的全球市場：按藥物類別、按產品類型、按應用、按分銷管道、按地區

Global Inhalable Drugs Market, By Drug Class (Inhaled Corticosteroids, Leukotriene modifiers, Long-acting beta agonists, Long-acting muscarinic antagonists, Others), By Product Type, By Application, By Distribution Channel, By Region

出版日期: 2023年12月27日 | 出版商:

Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球吸入器市場規模預計將從 2023 年的 348.6 億美元增至 2030 年的 566.8 億美元，預測期內複合年成長率為 7.2%。

報告範圍		報告詳情
基準年	2022年	2023/2024年市場規模	348.6億美元
實際資料	2018-2021	預測期	2023-2030
2023/2024-2030/2031預測期複合年成長率	7.20%	2030/2031價值預測	566.8億美元

圖 1. 2023 年按地區分類的吸入劑全球市場佔有率(%)

吸入藥物是經由肺部經呼吸道局部給藥時發揮快速治療效果的醫療物質。它對治療氣喘、慢性阻塞性肺病和囊腫纖維化肺部疾病特別有效。與透過胃腸道口服給藥相比，肺部為藥物吸收提供了巨大的表面積。吸入藥物繞過肝臟首過代謝，允許藥物直接快速輸送至肺組織並降低全身水平。與口服藥物相比，主要優點包括幾分鐘內快速起效、劑量更低、副作用更少。流行的吸入藥物包括治療氣喘和慢性阻塞性肺病的支氣管擴張劑，如沙丁胺醇、皮質類固醇、分散抗生素和胰島素。隨著全球肺部疾病的增加，吸入藥品市場預計將繼續穩定成長。

市場動態：.

全球吸入藥物市場受到氣喘和慢性阻塞性肺病等呼吸系統疾病全球盛行率不斷上升的推動。例如，2023年 3月16日，據世界衛生組織（WHO）稱，慢性阻塞性肺病（COPD）是全球第三大死因，2021年將有超過3億人患有氣喘。CD. COPD 每年導致超過 300萬人死亡。污染水平的增加和生活方式的改變導致肺部疾病病例數量的增加。該市場也受惠於吸入藥物在治療直接影響呼吸道疾病方面的卓越療效。定量吸入器 (MDI) 和乾粉吸入器 (DPI) 等給藥裝置的技術進步正在擴大新療法的機會。然而，與吸入藥物的開發和生產相關的高成本限制了更廣泛市場的成長。此外，有關肺部給藥系統的臨床試驗和產品核可的嚴格規定也是一個限制。然而，先進製劑和聯合治療的持續研究和開發可能會在預測期內開闢新的途徑。

本研究的主要特點

該報告對全球吸入藥物市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
它還闡明了各個細分市場的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球吸入藥物市場的主要企業。
該報告的見解使行銷人員和經營團隊負責人就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球吸入藥物市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過分析全球吸入藥物市場時所使用的各種策略矩陣來促進決策。

介紹
北美洲
美國
加拿大
歐洲
德國
英國
西班牙
法國
義大利
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
澳洲
韓國
東南亞國協
其他亞太地區
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
中東
海灣合作理事會國家
以色列
其他中東地區
非洲
北非
中部非洲
南非

第10章競爭形勢

公司簡介
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck &Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.

第11章章節

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI6512

Global inhalable drugs market size is expected to reach US$ 56.68 Bn by 2030, from US$ 34.86 Bn in 2023, exhibiting a CAGR of 7.2% during the forecast period.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023/2024:	US$ 34.86 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR:	7.20%	2030/2031 Value Projection:	US$ 56.68 Bn

Figure 1. Global Inhalable Drugs Market Share (%), By Region, 2023

Inhalable drugs are medical substances that can be administered locally through the respiratory tract via the lung for rapid therapeutic effects. They are particularly effective for treating lung conditions such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The lung provides huge surface area for drug absorption as compared to oral administration through the gastrointestinal tract. Inhalable drugs bypass hepatic first-pass metabolism for faster delivery of medications directly to the lung tissues and lower systemic levels. Some key advantages include rapid onset of action within minutes, lower dosing, and reduced side effects as compared to oral medications. Popular inhalable drugs include bronchodilators for asthma and chronic obstructive pulmonary disease like albuterol, corticosteroids, dispersible antibiotics, and insulin. With rising lung diseases globally, the inhalable drugs market is expected to grow steadily in the future.

Market Dynamics:

Global inhalable drugs market is driven by the growing prevalence of respiratory diseases such as asthma and COPD worldwide. For instance, on March 16, 2023, according to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and over 300 Mn people suffered from asthma in 2021, while over 3 Mn people die each year from COPD. Increasing pollution levels and changing lifestyles have contributed to the rising caseload of lung illnesses. The market also benefits from the superior therapeutic efficacy of inhalable drugs in treating conditions, affecting the respiratory tract directly. Technological advancements in drug delivery devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are expanding opportunities for novel therapies. However, high costs that are associated with development and production of inhalable drugs limit wider market growth. Additional constraints include stringent regulations around clinical trials and product approval for pulmonary drug delivery systems. Nevertheless, ongoing research and development (R&D) into advanced formulations and combination therapies could unlock new avenues over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global inhalable drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global inhalable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK plc, Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc., AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc, 3M Health Care, Allied Healthcare Products, Inc., CareFusion Corporation, GF Health Products, Inc., Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals and PARI Respiratory Equipment, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global inhalable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalable drugs market

Detailed Segmentation:

Global Inhalable Drugs Market, By Drug Class
- Inhaled Corticosteroids
- Leukotriene modifiers
- Long-acting beta agonists (LABAs)
- Long-acting muscarinic antagonists (LAMAs)
- Others
Global Inhalable Drugs Market, By Product Type
- Aerosol
- Dry powder Formulation
- Spray
- Others
Global Inhalable Drugs Market, By Application
- Respiratory Diseases
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
Global Inhalable Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Inhalable Drugs Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Top Companies in the Global Inhalable Drugs Market:
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Inhalable Drugs Market, By Drug Class
- Global Inhalable Drugs Market, By Product Type
- Global Inhalable Drugs Market, By Application
- Global Inhalable Drugs Market, By Distribution Channel
- Global Inhalable Drugs Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Growing prevalence of respiratory diseases
- Risk of misuse of inhalable medicines
- Emergence of new drug delivery technologies
Key Highlights
Regulatory Scenario
Recent Trends
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Inhalable Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Inhalable Drugs Market, By Drug Class, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Inhaled Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Leukotriene modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Long-acting beta antagonists (LABAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Long-acting muscarinic antagonists (LAMAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Inhalable Drugs Market, By Product Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Dry powder Formulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Inhalable Drugs Market, By Application, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Cystic Fibrosis
Allergic Rhinitis
Others
Non-respiratory Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Inhalable Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Inhalable Drugs Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Bn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profile
- GSK plc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
Analyst Views